(re)Imagine the future – life sciences perspective
Evaluating the impact of COVID-19 on life sciences sector and delves into artificial intelligence, machine learning, vaccine development and technology
COVID-19 has severely disrupted the pharmaceuticals and medtech R&D businesses, impacting the overall life sciences industry, which is today on the cusp of change. While this change brings with it some challenges, it also opens doors to new opportunities. Both pharmaceutical and medtech businesses have found themselves front and center supplying vitally important medical products to support patients in their time of need.
While the prevailing situation is an impediment to routine life, it has also led to multiple aspects to be redefined across all streams of life. While the race to find a remedy to cure the infection would continue to take place; more research & collaborations would be necessary to invent new vaccine for infection prevention. Let’s look at the bigger picture beyond just a vaccine for COVID-19.
This whitepaper on ‘(re)Imagine the Future – Life Sciences Perspective’ attempts to navigate through the present times and evaluate the impact of COVID-19 on various streams of businesses in Life sciences domain and further analyse areas on which the fraternity would be focusing on.
The paper also brings out the technology trends in Vaccine development, R&D efforts, collaborations and insights on the present & future businesses.
The highlights of the report:
- The challenge is the unavailability of the historical data & a regular new set of data emerging about this virus.
- India’s ambitions to get to $5 Trillion economy would be realized only if the share of MSMEs to GDP doubles from its current share of ~ 30 %.
- The times are ripe for the countries to rethink, reset & re-strategize than merely looking to capitalize on the short-term revenue gains.
- A comparative data analysis of all vaccines will be undertaken, the best amongst them would emerge and will be adopted for future generations as “The vaccine” for COVID-19.
- The growth of manufacturing would be synthetic if the investments in R&D don’t go up substantially.